BioSpace News Archive

Privately-held Oncologie will conduct a Phase II study of the combination study for patients who have failed at least one line of treatment for gastric or gastroesophageal cancer.

Coordination Pharmaceuticals Inc., a privately-held oncology drug development company announced that the first patient has been dosed in a Phase 1 study of CPI-200 in patients with advanced tumors.

Amongst its structural attributes, a protein’s secondary structural features – such as alpha helices, beta sheets, and other conformations – are critical parameters that must be assessed diligently.

Microbix Biosystems Inc. reports results for its third quarter and nine months of fiscal 2019, the three-month and nine-month periods ending June 30, 2019 (“Q3" & “YTD”), with record YTD sales, strong YTD sales growth, improving percentage gross margin, and progress on its strategic goals.

Danforth Advisors, LLC, the life science industry’s leading resource for operational accounting, finance support, CFO services and strategic advisory, announced the appointment of Warren Steinberg as Chief Financial Officer.

The Eastern Pathology Alliance (EPA) announces today that it is to offer Hepatitis C genotyping testing to the wider NHS nationally leveraging its investment in next generation sequencing assays.

Start Codon, a new model of life science and healthcare business accelerator, today announced it has partnered with Clustermarket, a leading online equipment sharing and booking platform and Science Entrepreneur Club, a life sciences network, to help drive the translation of world-class life science and healthcare research into commercially successful companies.

Assertio Therapeutics, Inc. announced it has entered into separate, privately negotiated exchange agreements with a limited number of holders of Assertio’s currently outstanding 2.50% Convertible Notes due 2021.

Quanta Dialysis Technologies Ltd, a pioneering British medical technology company developing a personal haemodialysis system for patient use at home and in the clinic, announces that it has selected Benchmark Electronics Inc., a global provider of manufacturing, engineering and design services, as its production partner for the SC+ haemodialysis machine.

AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, announced a research partnership with leading scientists in the Perelman School of Medicine at the University of Pennsylvania focused on studying the pathological mechanisms of TDP-43 misfolding and aggregation.